The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 07, 2020
Filed:
Nov. 24, 2015
Applicant:
Bioxcel Corporation, Branford, CT (US);
Inventors:
Assignee:
BIOXCEL CORPORATION, Branford, CT (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/05 (2006.01); A61K 45/06 (2006.01); A61K 38/07 (2006.01); A61K 31/69 (2006.01); A61K 31/573 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 38/05 (2013.01); A61K 31/573 (2013.01); A61K 31/69 (2013.01); A61K 38/07 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/57407 (2013.01); G01N 33/57423 (2013.01); G01N 2333/82 (2013.01); G01N 2800/52 (2013.01);
Abstract
The invention discloses a method of treating, preventing or ameliorating tumor or symptoms resulting from defective neurofibromatosis type-2 gene in a subject by administering to the subject a therapeutically effective amount of a ubiquitin-proteasome system inhibitor which inhibits or slows the growth of neurofibromatosis type-2-deficient tumor or associated symptoms. The invention also includes methods of diagnosis and screening of patients for neurofibromatosis type-2 and mesothelioma.